- Home
- CLLS vs NMAI Comparison
CLLS vs NMAI Comparison
Compare CLLS & NMAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CLLS | NMAI |
|---|---|---|
| Founded | 1999 | 2021 |
| Country | France | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 394.4M | 458.6M |
| IPO Year | 2014 | N/A |
Fundamental Metrics
Financial Performance| Metric | CLLS | NMAI |
|---|---|---|
| Price | $2.78 | $14.01 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $8.33 | N/A |
| AVG Volume (30 Days) | 12.5K | ★ 85.7K |
| Earning Date | 05-08-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 13.14% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.64 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $0.98 | N/A |
| P/E Ratio | ★ N/A | $21.86 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.48 | $11.99 |
| 52 Week High | $5.48 | $14.38 |
Technical Indicators
Market Signals| Indicator | CLLS | NMAI |
|---|---|---|
| Relative Strength Index (RSI) | 43.54 | 55.69 |
| Support Level | $2.65 | $13.60 |
| Resistance Level | $2.98 | $14.30 |
| Average True Range (ATR) | 0.11 | 0.23 |
| MACD | 0.02 | 0.01 |
| Stochastic Oscillator | 48.72 | 69.44 |
Price Performance
Historical ComparisonAbout CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.
About NMAI Nuveen Multi-Asset Income Fund of Beneficial Interest
Nuveen Multi-Asset Income Fund is a closed-end management investment company. The Fund dynamically invests in a portfolio of equity and debt securities of issuers located around the world. This dynamic investment uses a risk-based framework in which any amount can be allocated to an asset-class at any time. The Fund's investment objective is to provide total return through high current income and capital appreciation.